← Leaderboards
Claudia Abeijon
Detectogen, Inc.
$3,129,688
Attributed
$3,429,688
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $665.3K · FY2009–19$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,429,688 · 4
By mechanism
R44$1,928,638 · 1
R43$1,501,050 · 3
Top collaborators
- Antonio Campos-Neto2 shared
Others in their field
Top investigators on “Mass Spectrum Analysis”
- Paul S. Aisen · Cognition Therapeutics, Inc.$30,310,037
- Reisa A. Sperling · Banner Health$30,310,037
- Richard D Smith · Battelle Pacific Northwest Laboratories$28,842,237
- Ronald C Petersen · Mayo Clinic Coll Of Medicine, Rochester$28,666,849
- David Heimbrook · Leidos Biomedical Research, Inc.$27,692,696
- John Robert Yates · Scripps Research Institute, The$26,948,886
Research focus
Mass Spectrum AnalysisProteinsBaseSmall Business Innovation Research GrantVisceral LeishmaniasisUrineParasitesLeishmania InfantumCommunicable DiseasesFoundationsValidationAntigensDisease DiagnosisAntibodiesSensitivity And SpecificityDetectionDiagnosisProductionEnzyme-Linked Immunosorbent AssayLeishmania DonovaniMorbidity - Disease RateRecombinantsRecombinant ProteinsSampling
Grant awards (9)
Novel non-invasive antigen detection assay for the diagnosis of active visceral leishmaniasis and to monitor the therapy efficacy of this disease$651,346
R44 · FY2019 · AI · contact PI
Novel non-invasive antigen detection assay for the diagnosis of active visceral leishmaniasis and to monitor the therapy efficacy of this disease$665,346
R44 · FY2018 · AI · contact PI
Novel non-invasive antigen detection assay for the diagnosis of active visceral leishmaniasis and to monitor the therapy efficacy of this disease$611,946
R44 · FY2017 · AI · contact PI
Development of a protein-based antigen detection test for kala-azar$210,000
R43 · FY2016 · AI · contact PI
Development of a protein-based antigen detection test for kala-azar$210,000
R43 · FY2015 · AI · contact PI
Validation of a new VL vaccine candidate in dogs that significantly protects mice$300,000
R43 · FY2013 · AI · contact PI
Validation of a new VL vaccine candidate in dogs that significantly protects mice$300,000
R43 · FY2012 · AI · contact PI
Antigen Detection Assay for the Diagnosis of Visceral Leismaniasis$198,870
R43 · FY2010 · AI · contact PI
Antigen Detection Assay for the Diagnosis of Visceral Leismaniasis$282,180
R43 · FY2009 · AI · contact PI